© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to September
oral reversible-covalent FGFR4 kinase inhibitor
first sel. FGFR4i in clinical studies; for HCC
from biochemical HTS and SBDD
J. Med. Chem., Oct. 1, 2020
Novartis, Basel, CH
FGF401 (roblitinib) is a highly selective, reversible-covalent inhibitor of the kinase FGFR4, a receptor that can drive progression of certain cancers. The Novartis team found that the FGFR4 protein has…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.